DDInter220 DDInter875
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Blinatumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Blinatumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Blinatumomab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Blinatumomab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Blinatumomab may lead to a major life threatening interaction when taken with Infliximab
Blinatumomab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated